[New] By 2026, AI will play a more significant role in healthcare, from drug discovery to personalized treatment plans.
Data Canvas AI
[New] Commissioned by the UK government in 2014, if the rate of drug-resistant infections reached 100% by 2050, there would be an estimated 10 million deaths caused by drug-resistant infections.
PubMed Central (PMC)
[New] Roche reported that its experimental obesity drug CT-388 resulted in weight loss in a Phase 2 trial and that it plans to start Phase 3 trials this quarter.
MM+M - Medical Marketing and Media
[New] In 2026, more domestically developed biologics, including CAR-T therapies, antibody-drug conjugates, and novel monoclonal antibodies, are expected to reach late-stage trials or approval. / ChinaChina Briefing News
[New] J&J expects a more pronounced impact from new products in 2026, as it launched some key new products in 2025, like Inlexzoh / TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer and Imaavy for treating generalized myasthenia gravis.
Yahoo Finance
[New] In 2026, AI and automation are anticipated to solve talent gaps and economic shifts to drive resilient drug discovery and manufacturing.
BioPharm International
[New] With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the most of its head start with the Wegovy pill.
Fierce Pharma
[New] Structure's oral drug will enter Phase 3 trials in 2026.
CNBC
[New] If 2026 is the year that AI for drug development really takes flight, deal volumes could be much higher than we anticipate.
ING Think
[New] The US faces an escalating drug-pricing problem that could be addressed through the increased uptake of biosimilar therapies.
Center for Biosimilars
[New] Syngene and Bristol Myers Squibb extend their collaboration through 2035, integrating infrastructure and automation to accelerate long-term drug development.
Pharmaceutical Technology
[New] Google-backed Isomorphic Labs, often cited as a flagship of AI-first drug discovery, now expects its first clinical trials to begin by the end of 2026, later than initially anticipated.
Labiotech UG
[New] The proposal to lower drug pricing will help open up conversations about requiring hospitals and providers to slash their prices - which can be a top driver of health insurer premiums.
Health Care News for Insurance Brokers | J&R Report
[New] The pharmaceutical industry has opposed Trump's most-favored-nation push, arguing that it could weaken the dominance of the U.S. in biotech innovation and reduce future investment into novel treatments.
Health Care News for Insurance Brokers | J&R Report
[New] In 2026, we will see changes with how drugs are developed as pharmaceutical companies increasingly embrace new approach methodologies to manage toxicology risk.
Drug Discovery News Magazine
[New] 2026 will see the emergence of AI-native digital CROs that collapse drug discovery timelines by months, even years, by replacing physical experiments with virtual ones while creating an opportunity to reshore drug discovery and strengthen U.S. competitiveness.
Bessemer Venture Partners
[New] The Inflation Reduction Act is reshaping U.S. drug pricing by allowing Medicare to negotiate prices on high-expenditure, single-source drugs beginning in 2026, expanding to 60 drugs by 2030.
Insight Global
[New] While software automation has been well established in pharmaceutical workflows, 2026 will mark a turning point for physical automation in the corporate life sciences environment.
Digital Health Technology News
[New] Many pharmaceutical manufacturers, including Novo Nordisk, Astra Zeneca, Merck, Eli Lilly/BI, Takeda, Johnson & Johnson, Sanofi, and Intarcia Therapeutics, have late-stage pipeline products or recently marketed products that could significantly strengthen their portfolios.
Pharmacy Times
[New] The Food and Drug Administration has signaled that it plans to make approval of the influenza vaccine more difficult, so we may see less availability or no availability of flu vaccines as soon as next year.
Think Global Health
